Chinese drugmaker Sinopharm said that its mRNA COVID-19 vaccine against the Omicron variant has received government approval on Thursday to begin clinical trials. The company has built a 2 billion dose annual capacity production line in Shanghai and will continue to study the vaccine's efficacy.